Intravascular Large B-Cell Lymphoma

Watchlist

(log in to enable)

Retrieved

2021-01-23

Source

Orphanet

Trials

—

Genes

BCL6, BCL2, TNFRSF8, CD274, SMUG1, ACP3, LAMC2, KRT20, PRTN3, MME, KMT2A, IGH, IRF4, ALK, CSF3, CSF2, CRP, MS4A1, PWWP3A

Drugs

3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride, 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine, Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus, Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor, Autologous engineered anti -CD19 Chimeric Antigen Receptor (CAR +) T -cells ( KYMRIAH ), Axicabtagene ciloleucel ( YESCARTA ), Brentuximab vedotin ( ADCETRIS ), Enzastaurin hydrochloride, Everolimus ( AFINITOR, VOTUBIA ), Humanised Fc engineered monoclonal antibody against CD19, Humanised anti-CD37 monoclonal antibody conjugated to maytansinoid DM1, Ibrutinib ( IMBRUVICA ), Iodine (131I) tositumomab, Lenalidomide ( LENALIDOMIDE ACCORD, REVLIMID ), Mocetinostat, Obinutuzumab ( GAZYVA, GAZYVARO ), Pixantrone dimaleate ( PIXUVRI ), Polatuzumab vedotin ( POLIVY ), Pralatrexate ( FOLOTYN ), Recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors, Rituximab ( BLITZIMA, MABTHERA, TRUXIMA, RITEMVIA, RITUXAN, RITUZENA, RIXATHON, RIXIMYO, Ruxience ), Selinexor ( XPOVIO ), Tazemetostat ( TAZVERIK ), Valproic acid, sodium, Venetoclax ( VENCLEXTA, VENCLYXTO ), haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate

Interested in hearing about new therapies?

Intravascular large B-cell lymphoma (IVLBCL) is a very rare form of diffuse large B-cell lymphoma (see this term) characterized by the selective growth of lymphoma cells within the lumina of small blood vessels (especially the capillaries) that most often presents with a wide range of clinical manifestations (as potentially any tissue can be involved), with patients from Western countries more frequently manifesting with neurological and cutaneous symptoms while patients from Asian countries more frequently displaying hepatosplenomegaly and thrombocytopenia. IVLBCL is characterized by an absence of lymphadenopathy, an aggressive clinical course and a poor prognosis.